# VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics

> **NIH NIH P30** · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $893,894

## Abstract

PROJECT ABSTRACT
 Pediatric and adult rheumatic and musculoskeletal (MSK) diseases challenge the clinical researcher:
they affect the population across the lifespan, impact a broad range of patient-centered outcomes, are rarely
cured, and often have multiple possible treatment strategies. If properly addressed, these factors present
tremendous opportunities for improving patient care and outcomes of patients. The overarching goal of the
Brigham and Women’s Hospital (BWH) CCCR is to facilitate advancements in the methodologic sciences
supporting clinical research within the NIAMS pediatric and adult rheumatic and musculoskeletal (MSK)
disease missions.
 VERITY is organized around central scientific themes that can be applied to multiple rheumatic and
MSK diseases. The Cores address the following cross-cutting areas: 1) including patients in clinical trial
design, outcome selection, result interpretation, and dissemination; 2) integrating behavioral economics to
enhance benefits of known interventions, i.e., adherence to medications, engagement in physical activity and
weight loss; 3) extracting maximum information content from big data; 4) using smart technologies (mobile
health) to advance clinical research; and 5) disseminating knowledge and mentoring of local and national
rheumatic and MSK disease clinical researchers through distributed learning models. These scientific themes
will be approached through several Cores described in the following Specific Aims. 1. To strategically direct,
supervise, and provide financial accountability to VERITY and to train a broad group of local and national
investigators for patient-oriented clinical research in pediatric and adult rheumatic and MSK diseases.
(Administrative Core) 2. To develop and implement state of the art methods in innovative trials and
longitudinal comparative effectiveness studies for rheumatic and MSK disease research. (Methodology Core)
3. To support bioinformatic approaches to enhance utilization of large databases for phenotyping relevant
patients, and implementing biomarker, electronic medical record, and comparative effectiveness analyses.
(Bioinformatics Resource Core)

## Key facts

- **NIH application ID:** 10017653
- **Project number:** 5P30AR072577-04
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Daniel Hal Solomon
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $893,894
- **Award type:** 5
- **Project period:** 2017-09-20 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017653

## Citation

> US National Institutes of Health, RePORTER application 10017653, VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics (5P30AR072577-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10017653. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*